相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial
Yi-Zhou Jiang et al.
CELL RESEARCH (2021)
Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets
Yue Gong et al.
CELL METABOLISM (2021)
Molecular Features and Functional Implications of Germline Variants in Triple-Negative Breast Cancer
Ding Ma et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Molecular Classification of Breast Cancer
Julia Y. S. Tsang et al.
ADVANCES IN ANATOMIC PATHOLOGY (2020)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Expression of tumor-associated antigens in breast cancer subtypes
Giuseppe Curigliano et al.
BREAST (2020)
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Peter Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
T. Karn et al.
ANNALS OF ONCOLOGY (2020)
Prognostic Alternative mRNA Splicing Signature and a Novel Biomarker in Triple-Negative Breast Cancer
Qiang Liu et al.
DNA AND CELL BIOLOGY (2020)
Landscape of circulating tumour DNA in metastatic breast cancer
Andrew A. Davis et al.
EBIOMEDICINE (2020)
Unraveling the Genomic-Epigenomic Interaction Landscape in Triple Negative and Non-Triple Negative Breast Cancer
Jiande Wu et al.
CANCERS (2020)
Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance
Shen Zhao et al.
ONCOLOGIST (2020)
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
Antonio Marra et al.
NPJ BREAST CANCER (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers
Lei Wang et al.
THERANOSTICS (2020)
Comprehensive Proteomic Characterization Reveals Subclass-Specific Molecular Aberrations within Triple-negative Breast Cancer
Max Kosok et al.
ISCIENCE (2020)
A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival
Mustafa I. Jaber et al.
BREAST CANCER RESEARCH (2020)
Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies
Yi-Zhou Jiang et al.
CANCER CELL (2019)
Recent advances in triple negative breast cancer: the immunotherapy era
Antonio Marra et al.
BMC MEDICINE (2019)
Deep learning: new computational modelling techniques for genomics
Gokcen Eraslan et al.
NATURE REVIEWS GENETICS (2019)
Clinicopathological Features of Triple-Negative Breast Cancer Epigenetic Subtypes
Maggie L. DiNome et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
H. J. Burstein et al.
ANNALS OF ONCOLOGY (2019)
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study
Leisha A. Emens et al.
JAMA ONCOLOGY (2019)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
Sherene Loi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics
Jelmar Quist et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications
Pascal Jezequel et al.
BREAST CANCER RESEARCH (2019)
Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer
Thomas A. Adams et al.
MODERN PATHOLOGY (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Andrew Tutt et al.
NATURE MEDICINE (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Integrative analysis of the intertumoral heterogeneity of triple-negative breast cancer
Alec M. Chiu et al.
SCIENTIFIC REPORTS (2018)
Classification of triple-negative breast cancers based on Immunogenomic profiling
Yin He et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Epigenetic profiling for the molecular classification of metastatic brain tumors
Javier I. J. Orozco et al.
NATURE COMMUNICATIONS (2018)
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
Jake R. Conway et al.
GENOME MEDICINE (2018)
Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study
Weikai Xiao et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Sung-Bae Kim et al.
LANCET ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes
Hiroko Masuda et al.
ONCOTARGET (2017)
Somatic gene mutation analysis of triple negative breast cancers
J. L. Dillon et al.
BREAST (2016)
Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis
Sebastian Moran et al.
LANCET ONCOLOGY (2016)
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group
Carsten Denkert et al.
MODERN PATHOLOGY (2016)
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting
Luisa Carbognin et al.
ONCOLOGIST (2016)
The cancer immunogram
Christian U. Blank et al.
SCIENCE (2016)
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes A Systematic Review
Sasha E. Stanton et al.
JAMA ONCOLOGY (2016)
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
Brian D. Lehmann et al.
PLOS ONE (2016)
Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer
Yi-Rong Liu et al.
BREAST CANCER RESEARCH (2016)
Clinical implications of the intrinsic molecular subtypes of breast cancer
Aleix Prat et al.
BREAST (2015)
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression
Maggie C. U. Cheang et al.
ONCOLOGIST (2015)
Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value
Clare Stirzaker et al.
NATURE COMMUNICATIONS (2015)
The Proteomic Landscape of Triple-Negative Breast Cancer (vol 11, pg 630, 2015)
Robert T. Lawrence et al.
CELL REPORTS (2015)
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Matthew D. Burstein et al.
CLINICAL CANCER RESEARCH (2015)
Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour
Zeinab Elsawaf et al.
BREAST (2013)
Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer
Aleix Prat et al.
ONCOLOGIST (2013)
Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up
L. Malorni et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
分享论文
